Development and content validation of the Satisfaction and Experience Questionnaire for Granulocyte Colony-Stimulating Factor (SEQ-G-CSF).

摘要: Several options for granulocyte colony-stimulating factor (G-CSF) prophylaxis of chemotherapy-induced febrile neutropenia are available to patients worldwide. We have developed a novel patient-reported outcome measure, the Satisfaction and Experience Questionnaire G-CSF (SEQ-G-CSF), help understand patients’ perspectives satisfaction with different options. Three oncology nurses 40 adult in United States were enrolled participated focus group discussions develop refine SEQ-G-CSF. Nurses had ≥ 5 years experience treating currently involved management receiving prophylaxis. The breast cancer, lung non-Hodgkin lymphoma, or prostate cancer (10 each group) via injection on-body injector (OBI) device. preliminary SEQ-G-CSF contained an item relevance questionnaire three SEQ modules (sociodemographic, medical history, G-CSF–related healthcare characteristics questionnaires). Twenty-one (53% total sample size) discussed their G-CSF. Their most common experiences effectiveness, convenience benefits OBI, relationships providers. Side effects having undergo additional treatment also reported. aspects included OBI effectiveness treatment; dissatisfaction inconvenience (having return clinic next day administration injection) insurance approval process. was finalized after rounds cognitive interviews includes five domains related general (one item), burden (four items), travel (two time compliance items). is instrument that quantifies patient’s using 13 easy-to-understand items. This study provides evidence content validity Although further psychometric testing required, may be useful addition clinical trials, observational studies, practice.